Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215410 | 0.91 | XDH (0.55) | XDHMRGPRX4NPC1RAB9A | |
| SCHEMBL6215963 | 0.90 | MAOB (0.60) | XDHMRGPRX4MAOBSLC6A4 | |
| SCHEMBL6216328 | 0.88 | NPC1 (0.52) | XDHMRGPRX4NPC1RAB9AMAOB | |
| SCHEMBL6211864 | 0.86 | MRGPRX4 (0.62) | MRGPRX4NPC1RAB9ASLC6A4 | |
| SCHEMBL6211977 | 0.82 | MRGPRX4 (0.48) | XDHMRGPRX4NPC1RAB9AMAOB | |
| SCHEMBL6213507 | 0.81 | MRGPRX4 (0.56) | XDHMRGPRX4NPC1RAB9AMAOB | |
| Hydrochloric Acid SCHEMBL28516472 | 0.81 | F2 (0.56) | XDHMRGPRX4 | |
| SCHEMBL23677222 | 0.79 | NOS2 (0.46) | XDHMRGPRX4MAOBMAOASLC6A4 | |
| SCHEMBL1197763 | 0.79 | MAPT (0.54) | XDHMRGPRX4SLC6A4 | |
| SCHEMBL4593423 | 0.79 | NOS2 (0.46) | XDHMRGPRX4MAOBMAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | XDH 834/4885MRGPRX4 362/4885NPC1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.